secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2023-11-28T23:59:59+00:00
Accession:  0000950170-23-066248
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics announces 50% workforce reduction, restructuring to focus on CAN-3110 and enLIGHTEN platform
--------------------------------------------------------------------------------

- Approximately 50% workforce reduction; one-time restructuring charge of ~$0.7M in Q4 2023.
- Cash runway extended into Q4 2024; company prioritizes CAN-3110 development and enLIGHTEN platform.
- Key CAN-2409 readouts in 2024: NSCLC overall survival (Q2), pancreatic interim (Q2), prostate (Q4).
- Company will explore partnering opportunities for CAN-2409 to reduce commercial manufacturing costs.
- Initial CAN-3110 repeated injection data in recurrent high-grade glioma expected H2 2024; new enLIGHTEN data Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023066248/0000950170-23-066248-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023066248/cadl-20231126.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-066248

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer